In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Seres Health closes $10.6mm B round

Executive Summary

Seres Health Inc. (developing Ecobiotic therapeutics for various diseases by targeting the underlying biology of the microbiome) raised $10.6mm in its Series B round to returning shareholders Flagship Ventures and Enso Ventures, and first-time backers Mayo Clinic (which also concurrently entered into a drug discovery and development partnership with the company), Alexandria Venture Investments, and six private investors. Funds will support development of Seres' pipeline, which includes lead candidate SER109 (Phase I) for C. difficile.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies